UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway

Frontiers in immunology, 2020-12, Vol.11, p.599417-599417

2020

Volltextzugriff (PDF)

Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects

Drugs in R&D, 2024-03, Vol.24 (1), p.97-108

2024

Volltextzugriff (PDF)

Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist

European journal of clinical pharmacology, 2017-02, Vol.73 (2), p.151-156

2017

Volltextzugriff (PDF)

Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects

Pharmacology, 2014-01, Vol.94 (3-4), p.148-156

2014

Volltextzugriff (PDF)

Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo

Clinical and translational science, 2023-07, Vol.16 (7), p.1220-1231

2023

Volltextzugriff (PDF)

Effect of nivasorexant ( ACT ‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects

Pharmacology research & perspectives, 2023-10, Vol.11 (5), p.e01143-e01143

2023

Volltextzugriff (PDF)

Mechanisms of benzarone and benzbromarone-induced hepatic toxicity

Hepatology (Baltimore, Md.), 2005-04, Vol.41 (4), p.925-935

2005

Volltextzugriff (PDF)

Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a1 receptor) antagonist

Pharmacology research & perspectives, 2023-08, Vol.11 (4), p.e01112-n/a

2023

Volltextzugriff (PDF)

Value of Assessing 1‐Hydroxymidazolam in Drug‐Drug Interaction Studies with Midazolam as a Substrate of Cytochrome P450 3A

Journal of clinical pharmacology, 2024-09, Vol.64 (9), p.1123-1129

2024

Volltextzugriff (PDF)

0100 Excretion of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating Women

Sleep (New York, N.Y.), 2024-04, Vol.47 (Supplement_1), p.A44-A44

2024

Volltextzugriff (PDF)

Impact of the Selective Orexin‐1 Receptor Antagonist ACT‐539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects

Journal of clinical pharmacology, 2020-07, Vol.60 (7), p.931-941

2020

Volltextzugriff (PDF)

Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313

Progress in neuro-psychopharmacology & biological psychiatry, 2021-06, Vol.108, p.110166, Article 110166

2021

Volltextzugriff (PDF)

First‐in‐human study with ACT‐539313, a novel selective orexin‐1 receptor antagonist

British journal of clinical pharmacology, 2020-07, Vol.86 (7), p.1377-1386

2020

Volltextzugriff (PDF)

Transfer of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating Women

Journal of clinical pharmacology, 2024-10, Vol.64 (10), p.1278-1287

2024

Volltextzugriff (PDF)

Thorough QT Analysis of a Single Dose of Pacritinib: Results of the PAC107 Study

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S203-S203

2024

Volltextzugriff (PDF)

MPN-302 Thorough QT Analysis of a Single Dose of Pacritinib: Results of the PAC107 Study

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S427-S427

2024

Volltextzugriff (PDF)

Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects

Clinical drug investigation, 2023-11, Vol.43 (11), p.827-837

2023

Volltextzugriff (PDF)

First‐in‐man study of ACT‐709478, a novel selective triple T‐type calcium channel blocker

Epilepsia (Copenhagen), 2019-05, Vol.60 (5), p.968-978

2019

Volltextzugriff (PDF)

Authors’ Reply to Srinivas: “Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag”

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2015-10, Vol.15 (5), p.373-374

2015

Volltextzugriff (PDF)

Multiple‐ascending doses of ACT‐1014‐6470, an oral complement factor 5a receptor 1 (C5a1 receptor) antagonist: Tolerability, pharmacokinetics and target engagement

British journal of clinical pharmacology, 2023-01, Vol.89 (1), p.380-389

2023

Volltextzugriff (PDF)

Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug

CNS drugs, 2020-03, Vol.34 (3), p.311-323

2020

Volltextzugriff (PDF)

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2015-06, Vol.15 (3), p.195-203

2015

Volltextzugriff (PDF)

Mechanisms of liver steatosis in rats with systemic carnitine deficiency due to treatment with trimethylhydraziniumpropionate

Journal of lipid research, 2003-01, Vol.44 (1), p.144-153

2003

Volltextzugriff (PDF)

Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment

British journal of clinical pharmacology, 2016-08, Vol.82 (2), p.369-379

2016

Volltextzugriff (PDF)

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects

British journal of clinical pharmacology, 2015-10, Vol.80 (4), p.670-677

2015

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(38)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway

Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects

Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist

Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects

Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo

Effect of nivasorexant ( ACT ‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects

Mechanisms of benzarone and benzbromarone-induced hepatic toxicity

Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a1 receptor) antagonist

Value of Assessing 1‐Hydroxymidazolam in Drug‐Drug Interaction Studies with Midazolam as a Substrate of Cytochrome P450 3A

0100 Excretion of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating Women

Impact of the Selective Orexin‐1 Receptor Antagonist ACT‐539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects

Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313

First‐in‐human study with ACT‐539313, a novel selective orexin‐1 receptor antagonist

Transfer of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating Women

Thorough QT Analysis of a Single Dose of Pacritinib: Results of the PAC107 Study

MPN-302 Thorough QT Analysis of a Single Dose of Pacritinib: Results of the PAC107 Study

Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects

First‐in‐man study of ACT‐709478, a novel selective triple T‐type calcium channel blocker

Authors’ Reply to Srinivas: “Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag”

Multiple‐ascending doses of ACT‐1014‐6470, an oral complement factor 5a receptor 1 (C5a1 receptor) antagonist: Tolerability, pharmacokinetics and target engagement

Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag

Mechanisms of liver steatosis in rats with systemic carnitine deficiency due to treatment with trimethylhydraziniumpropionate

Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects

Suchergebnisse filtern